NBHL ltd. | News archives > Announcement of Agreements with ReCentrics Biotechnology Co. Ltd. and NBHL for Global Collaboration to Development and Commercialize GPCR Antibody Therapies

News archives

Home > News archives > Announcement of Agreements with ReCentrics Biotechnology Co. Ltd. and NBHL for Global Collaboration to Development and Commercialize GPCR Antibody Therapies

Announcement of Agreements with ReCentrics Biotechnology Co. Ltd. and NBHL for Global Collaboration to Development and Commercialize GPCR Antibody Therapies

Aug 24,2021 -- Updated 16:31 +0900 (GMT)

NBHL has singed the Agreements with ReCentrics Biotechnology Co. Ltd. and NBHL for Global Collaboration to Development and Commercialize GPCR Antibody Therapies.

Click here for details.

Recent Posts
Completion of the Series C funding to advance pipeline of novel GPCR antibodies
Announcement of a grant of patent for innovative new high-throughput single-cell analysis technology in US 2022.03.29.
NBHL will participate in BIO-Europe Spring 2022 – Digital.
NBHL will participate in GLOBAL START UP CONNECTION JAPAN and Digital RESI
NBHL will participate in Botech Showcase (Vertual).
Closing of the Series C funding to advance pipeline of novel GPCR antibodies
Announcement of Agreements with ReCentrics Biotechnology Co. Ltd. and NBHL for Global Collaboration to Development and Commercialize GPCR Antibody Therapies
NBHL will participate in BIO-Europe 2020 – Digital.
NBHL will be present at BioJapan 2020 in Yokohama, Japan
NBHL will participate in BioPharm America 2020 – Digital
NBHL will attend Discovery on Target 2020 – Virtual.
NBHL will participate in ChinaBio Partnering Forum 2020 – Digital
No opposition filed against NBHL’s European patent for anti-CCR7 antibodies
NBHL announces poster presentation at Antibody Engineering & Therapeutics Asia 2020 in Kyoto, Japan
NBHL will attend BIO CEO & Investor Conference 2020 in New York, USA
NBHL to present at Antibody Engineering & Therapeutics 2019 in San Diego, USA
NBHL will attend BIO-Europe 2019 in Hamburg, Germany.
NBHL will attend BIO Investor Forum 2019 in San Francisco, USA
NBHL to present at the FESTIVAL OF BIOLOGICS 2019 in Basel, Switzerland
NBHL will be present at BioJapan 2019 in Yokohama, Japan
Past log
2022.4
2022.3
2022.1
2021.8
2020.10
2020.9
2020.8
2020.4
2020.2
2019.12
2019.11
2019.10
2019.9
2019.5
2019.3
2018.10
2018.8
2018.3
2016.11
2016.9
2016.7
2016.6
2016.5
2016.3
2015.9
2014.11

News archives

Announcement of Agreements with ReCentrics Biotechnology Co. Ltd. and NBHL for Global Collaboration to Development and Commercialize GPCR Antibody Therapies

NB Health Laboratory